Dietmar Hopp: SAP Wealth and the Model of Regional Systems Philanthropy

Most billionaire philanthropy reads the same way. A foundation is established. A naming gift is made. A press release announces it. The wealthy donor's name is added to a hospital wing or a university building. The capital is converted into reputation. The institution being funded is essentially a marketing vehicle.

Dietmar Hopp's philanthropy is not that. The SAP co-founder has spent thirty years turning SAP-derived wealth into permanent regional infrastructure in the Rhine-Neckar metropolitan region — medical research capability, pediatric oncology, neonatal screening, public movement infrastructure, climate education, dementia care, STEM education, biotech anchor capital. The Hopp Foundation operates almost like a parallel regional development actor. It does not fund outcomes. It funds the systems that produce outcomes.

The most accurate description of what Hopp has built is *regional systems philanthropy*. It is much more interesting than the conventional billionaire-foundation framing — and it is one of the most distinctive examples of European founder capitalism on record.

This is part 3 of the SAP Founders Cluster on Startuprad.io. Friday: the tribute to Claus Wellenreuther. Saturday: Hasso Plattner and SAP as Europe's invisible operating system. Tomorrow: Hans-Werner Hector and Germany's STEM talent pipeline.

Executive Summary

Hopp's arc is built in three distinct acts. First, as SAP's commercial engine and CEO 1988-1998, he turned a five-person partnership rejected at IBM into a company that defined enterprise software. Second, after stepping back from SAP in 2005, he applied the founder mentality to German biotechnology through dievini Hopp BioTech — anchoring CureVac for fifteen years, building a €1.4 billion+ patient-capital biotech position, and becoming the financial counterweight that protected German vaccine sovereignty when the Trump administration attempted to acquire CureVac in March 2020. Third, through the Dietmar Hopp Stiftung (founded 1995) and TSG 1899 Hoffenheim, he has systematically reinvested his fortune into the medical, educational, sporting, and civic infrastructure of his home region — at a scale the foundation states has exceeded €1 billion over its first 25 years.

The piece worth writing is not about the money. It is about the pattern: permanent institutions, regional compounding, capability creation, long-duration utility. *"How do we permanently improve the capability of this region?"* is the question Hopp's philanthropy answers, repeatedly, across seven distinct domains.

Key Takeaways

• Born April 26, 1940, Heidelberg; raised in Hoffenheim. Diplom-Ingenieur (TH Karlsruhe, now KIT), 1965. IBM Germany 1966-1972 (Stuttgart, then Mannheim from 1968). Co-founded SAP April 1972 with Plattner, Tschira, Hector, Wellenreuther.

• SAP CEO 1988-1998. Took SAP public on the Frankfurt and Stuttgart exchanges in October 1988. NYSE listing 1998. Net worth: Forbes 2015 $7.2 billion; Bloomberg current ~$13.3 billion.

• Dietmar Hopp Stiftung gGmbH founded 1995. Endowed in 1996 with a majority of his SAP shares; by 2006 specified as approximately 70 percent of his net wealth at the time, valued then at around €400 million. The foundation states distributions have exceeded €1 billion over its first 25 years.

• dievini Hopp BioTech Holding GmbH & Co. KG. Formalised around 2005. By 2007 ~€320 million invested across 15 biotech companies; total deployment to date exceeds €1.4 billion. Patient-capital, anti-cyclical, board-involvement investment style — operates differently from venture capital in ways that proved decisive for CureVac.

• CureVac was the defining biotech bet. Hopp invested through dievini from 2005. As largest shareholder, his public rejection of the Trump administration's March 2020 acquisition attempt — *"We want to develop a vaccine for the whole world and not individual countries"* — became the moment German vaccine sovereignty crystallised. KfW invested €300 million in CureVac in June 2020. The vaccine candidate ultimately failed in late-stage trials (47 percent efficacy June 2021). BioNTech acquired CureVac for $1.25 billion in December 2025.

• TSG 1899 Hoffenheim total investment exceeds €350 million. From village amateur side in 1989 to Bundesliga 2008. Built the 30,000-seat Rhein-Neckar-Arena (now PreZero Arena) for €100M. Granted 50+1 majority exemption in 2015 ("Lex Leverkusen"). Voting majority transferred back to the club Nov 29, 2023, restoring 50+1 compliance.

• The seven pillars of regional systems philanthropy: medical infrastructure, "alla hopp!" public movement infrastructure (19 parks, ~€45M), youth and amateur sports beyond Hoffenheim, climate and environmental education (Klima Arena Sinsheim), education and STEM, elderly care and dementia, and neonatal diagnostics (screening centre processing >140,000 newborns annually across three federal states).

The arc from Hoffenheim to Walldorf

Hopp was born in April 1940 in Heidelberg and raised in Hoffenheim, the small village in the Kraichgau region of Baden-Württemberg that would later become central to both his philanthropic and sporting identity. The family history includes a difficult chapter, sensitively but factually documented: his father Emil Hopp, a schoolteacher, was an SA-Truppführer who led the destruction of the Hoffenheim synagogue during the Kristallnacht pogrom of November 1938 — nearly two years before Dietmar's birth. Dietmar Hopp bears no personal complicity in those events; he has acknowledged the history and supported a film project documenting the persecution of Jewish brothers from Hoffenheim during that period.

The post-war environment shaped him in specific ways. He collected and sold scrap iron for pocket money as a boy. He gave private maths tutoring and sold garage doors during Germany's Wirtschaftswunder. He told his mother he wanted to become a millionaire. He completed his Abitur at the gymnasium in Sinsheim around 1959, served roughly a year of military duty, then studied telecommunications engineering at the Technische Hochschule Karlsruhe — now the Karlsruhe Institute of Technology, where his future SAP co-founder Hasso Plattner was also an alumnus. He graduated in 1965 with a Diplom-Ingenieur.

He chose IBM Germany over a teaching career for what he has stated frankly as the practical reason: *"they paid the most."* Six years at IBM in Stuttgart and then Mannheim, working as a software developer and then systems consultant, gave him exposure to enterprise-scale computing and the dual fluency — technical depth plus commercial acumen — that would become his trademark at SAP. The 1971 ICI Östringen project, modernising the order processing for ICI's nylon fibre plant, became the technical prototype for what the five Mannheim engineers wanted IBM to back. When IBM cancelled the broader Xerox migration project and rejected their pitch to build a standardised product business, the five resigned and founded SAP in 1972.

At SAP, Hopp was the commercial engine to Hasso Plattner's technical vision. He was known as *"Vadder Hopp"* — Father Hopp — for a paternalistic but demanding leadership style built on flat hierarchies (four to six layers when Deutsche Bank had twenty-six), employee-first benefits unusual for the era, and what he summarised in a seminal 1997 culture speech as *"a willingness to handle criticism and conflicts; customer orientation; a climate of trust and generosity which accommodates original thinkers; an organization that tolerates mistakes."* As CEO from 1988 through 1998 he led SAP's growth from approximately 2,700 to 19,000 employees, took the company public in 1988, drove the international expansion that took R/3 into the United States, and oversaw the listing on the NYSE in 1998. He stepped down from the Executive Board in 1998 with Klaus Tschira on the same day. He left the Supervisory Board in 2003 and departed the company entirely in 2005.

The seven pillars of regional systems philanthropy

Most accounts of the Dietmar Hopp Stiftung focus on the Hopp Children's Tumor Center Heidelberg — KiTZ — which is unquestionably the foundation's most visible philanthropic project. KiTZ is genuinely important. But it is one example of a broader pattern that becomes visible only when the full scope of the foundation's work is taken together. There are seven distinct pillars, and the pattern they trace is what makes Hopp's philanthropy structurally different from the usual billionaire foundation.

1. Medical infrastructure — the strongest pillar

This is not donations. It is capability building. The Hopp Foundation has constructed, over thirty years, an integrated medical-research stack concentrated in the Rhine-Neckar region: pediatric oncology, cancer research, neuro-oncology, stem-cell research, molecular medicine, translational medicine, neonatal diagnostics, and precision medicine. The institutions repeatedly supported include Heidelberg University Hospital, KiTZ, the German Cancer Research Center (DKFZ), the National Center for Tumor Diseases (NCT Heidelberg), and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM).

The KiTZ commitment alone is substantial — the foundation provided €43 million to establish the Hopp Children's Cancer Center and an additional €21 million in 2023 to build a global molecular data repository and clinical study center expansion. KiTZ is a research-and-clinical institution sitting at the intersection of pediatric oncology, translational medicine, molecular diagnostics, genomic analysis, and the integration of research with clinical application. That places it considerably closer to strategic medical infrastructure than to conventional billionaire philanthropy. It changes outcomes for children with cancer in a way a hospital wing named for a donor does not.

Around KiTZ sit additional commitments: €15 million to NCT Heidelberg for individualised cancer medicine, €20 million to Heidelberg University Hospital for a new neuro-oncology research center, €7.5 million initial and €15 million total to HI-STEM (co-founded with DKFZ in 2008). Hopp has built what is, by any reasonable assessment, one of Europe's most coherent privately-funded medical-research clusters.

2. "alla hopp!" — the public movement infrastructure

The most underrated project the foundation has undertaken is also one of the cheapest by foundation standards. The "alla hopp!" initiative funded the construction of 19 large public movement and recreation parks across the Rhine-Neckar region — intergenerational public spaces combining exercise infrastructure, playgrounds, social meeting places, sports facilities, and mobility infrastructure. The Stiftung states that approximately €45 million was invested into the project. The facilities were subsequently transferred to municipalities for ongoing operation.

What makes alla hopp! diagnostically important is what it reveals about the foundation's pattern: Hopp funds permanent public infrastructure that becomes part of regional civic life, then hands it over for local stewardship. He is not seeking naming-rights credit. He is building usable durable assets, then walking away.

3. Youth and amateur sports beyond Hoffenheim

Most outsiders know only TSG 1899 Hoffenheim. Hopp's grassroots-sports philanthropy is much broader: local sports clubs, youth training infrastructure, community exercise facilities, amateur-level support, and school-based movement initiatives across Baden-Württemberg. None of it generates the public-relations attention Hoffenheim does. All of it is civic infrastructure in the same pattern as alla hopp!.

4. Climate and environmental education

The Klima Arena in Sinsheim opened in October 2019. It combines climate education, interactive science communication, sustainability programming, and citizen-awareness initiatives. Baden-Württemberg's Premier Winfried Kretschmann attended the opening. The significance is that Hopp's philanthropic interest expanded from medicine and sports into long-term societal-resilience themes — a domain where the conventional billionaire-philanthropy template does not typically reach.

5. Education and science

Schools, STEM education, university partnerships, technical education, research infrastructure. KIT Karlsruhe is funded. Heidelberg-linked institutions are funded. Science education programs in the region are funded. The continuity with SAP is direct: engineering culture, systems thinking, applied science, and technical education — the same intellectual substrate that produced SAP itself.

6. Elderly care and dementia

This is the least publicly visible pillar and arguably the most humane. The foundation supports dementia-care institutions, elderly-support systems, and care technologies — including *Tovertafeln*, the interactive care systems developed for cognitively impaired patients. It is the kind of philanthropy that produces no glamorous public moments. It also broadens the foundation's footprint beyond the elite-science, sports, and biotech narratives the press more commonly carries.

7. Neonatal diagnostics

This pillar is the most surprising. The Hopp Foundation funded the development of metabolic screening infrastructure for newborns. According to Stiftung material, the screening center processes samples from more than 140,000 newborns annually across Baden-Württemberg, Rhineland-Palatinate, and Saarland. Three federal states, one publicly-funded family-office capability. This is genuine public-health infrastructure — the kind that quietly catches metabolic disorders early enough for intervention to change outcomes for the rest of an affected child's life.

The dievini biotech bet and the CureVac moment

Parallel to the Stiftung's regional infrastructure work, Hopp built a substantial biotech investment vehicle. dievini Hopp BioTech Holding GmbH & Co. KG, formalised around 2005 from earlier investments dating to ~2000 (Cytonet, a cell-therapy company in Weinheim), is managed by Friedrich von Bohlen und Halbach — a biochemist and a descendant of the Krupp dynasty who previously founded LION Bioscience AG — and was co-led by Christof Hettich, the Mannheim attorney who provided legal and governance architecture until his unexpected death in February 2026. By 2007 dievini had already invested approximately €320 million across fifteen biotech companies; total deployment to date exceeds €1.4 billion. The portfolio includes Heidelberg Pharma (which Hopp rescued from bankruptcy), AC Immune in Lausanne, Cosmo Pharmaceuticals in Milan, GPC Biotech, Wilex, and Apogenix.

The defining bet, however, was CureVac. Hopp anchored the Tübingen-based mRNA pioneer from 2005 — for more than a decade as essentially the sole major owner, injecting over €80 million by 2012. The Bill and Melinda Gates Foundation co-invested $52 million in March 2015 for HIV and tuberculosis programs, validating the platform pre-COVID. When the pandemic struck and the Trump administration in March 2020 reportedly attempted to acquire CureVac or secure US-exclusive rights to its vaccine for approximately $1 billion, Hopp's public response defined the moment: *"It goes without saying that it cannot be that a German company develops the vaccine and that it is used exclusively in the USA."* German Economics Minister Peter Altmaier declared on national television: *"Germany is not for sale."* The KfW state-owned bank invested €300 million in CureVac in June 2020 for an approximate 23 percent stake. GlaxoSmithKline followed with €150 million for 10 percent. CureVac listed on NASDAQ in August 2020.

The vaccine candidate failed. The Phase 3 trial in June 2021 returned only 47 percent efficacy. The company pivoted to second-generation programs with GSK. In December 2025 BioNTech completed the acquisition of CureVac for $1.25 billion in an all-stock transaction. Hopp's twenty-year journey with the company closed with the absorption of Germany's second mRNA pioneer into the Strüngmann-anchored first.

The CureVac arc demonstrates what dievini is structurally for. A conventional venture fund operating on a seven-to-ten year cycle would have had to exit CureVac long before COVID validated the platform. dievini did not. The patient-capital, family-office model — without LP reporting cycles, fund-life clocks, or exit obligations — was the structural condition that allowed Hopp to anchor the company through fifteen years of pre-commercial scientific work. The same structure characterises the Strüngmann family office's anchor position in BioNTech. Both are examples of why German operator-grade family-office capital functions differently from US-style venture investment for deep-tech, multi-decade bets.

TSG 1899 Hoffenheim: the visible controversy

Of all Hopp's projects, TSG 1899 Hoffenheim is the most public, the most controversial, and the one most often mistaken for the centre of his identity. The club is from the village where he grew up; he began supporting it financially in 1989, when it had just been relegated to the lowest tier of German amateur football. From 2005 he intensified the investment dramatically. Promotion to the second division followed in 2007; promotion to the Bundesliga in 2008. Hopp financed construction of the 30,000-seat Rhein-Neckar-Arena, now PreZero Arena, for €100 million. Total investment in the club is estimated to exceed €350 million.

The controversy is German football's 50+1 rule, which requires club members to retain majority voting rights and prevents private commercial control. In 2015 Hopp was granted a formal exemption under the "Lex Leverkusen" provision allowing majority ownership for investors who had provided uninterrupted significant funding for more than twenty years. For Germany's "ultra" fan groups, that exemption made Hopp the personification of football's commercialisation. The conflict escalated through repeated protests, a 2011 "Soundgate" incident involving directional speakers used to drown out anti-Hopp chants, surveillance cameras and microphones installed in the stadium for fan-protest prosecution, and ultimately the February 29, 2020 Sinsheim incident in which Bayern Munich's players stopped competitively contesting the final 13 minutes of a 6-0 win in protest of insulting banners directed at Hopp.

In March 2023 Hopp announced he was returning his majority voting rights to the club. The transfer was completed on November 29, 2023, bringing TSG Hoffenheim back into 50+1 compliance. He explained the decision as ending the *"mistrust and hostilities"* that his special status had caused. Subsequent reporting in April 2025 by *Kicker* magazine alleged that Hopp continued to wield influence through his close personal relationship with football agent Roger Wittmann of ROGON. German football media have scrutinised that relationship and the questions it raises about informal influence and club governance. In January 2026 Hopp announced an external audit had found "no legal wrongdoing" but committed to improving internal processes.

The deeper pattern

Hopp's philanthropy repeatedly focuses on the same underlying things: systems, institutions, infrastructure, capability creation, regional compounding, long-duration utility. It does less of: art-world visibility, celebrity activism, ideological campaigning, global branding philanthropy.

It does more of: permanent institutions, medical capability, science infrastructure, public facilities, regional reinforcement, durable usefulness.

That is why the Rhine-Neckar region matters so much in understanding him. He is not building a global personal brand. He is asking — repeatedly, across seven distinct domains — *how do we permanently improve the capability of this region?* The question, and the consistent answer in capital terms, is what makes his work structurally different from the standard billionaire-foundation template. The most accurate label for what he does is regional systems philanthropy.

That is the lesson worth taking from the Hopp model. It is not that other founders should fund children's cancer centres. It is that capability creation in a defined region, sustained for decades, produces compounding social returns of a kind that diffuse global giving does not.

Tomorrow we close the cluster with Hans-Werner Hector — the silent SAP co-founder who left in 1997 in dispute and spent the next three decades constructing Germany's STEM talent pipeline, also quietly, also at scale.

Frequently Asked Questions

Who is Dietmar Hopp? Dietmar Hopp (born April 26, 1940, Heidelberg) is a co-founder of SAP, a major German biotech investor through dievini Hopp BioTech, and one of Germany's largest private philanthropists through the Dietmar Hopp Stiftung. He served as SAP CEO from 1988 to 1998. His estimated net worth is in the range of $13 billion.

What is the Dietmar Hopp Stiftung? A private charitable foundation Hopp founded in 1995 and endowed in 1996 with a majority of his SAP shares. The foundation states that distributions have exceeded €1 billion over its first 25 years. Its work is concentrated in the Rhine-Neckar metropolitan region across seven domains: medical infrastructure, public movement infrastructure ("alla hopp!"), youth and amateur sports, climate education, education and STEM, elderly care, and neonatal diagnostics.

What is KiTZ Heidelberg? The Hopp Children's Tumor Center, a pediatric oncology research and clinical institution at Heidelberg University Hospital. The Hopp Foundation provided €43 million for its establishment and an additional €21 million in 2023 to expand its global molecular data repository and clinical study capability. It integrates pediatric oncology, translational medicine, molecular diagnostics, genomic analysis, and clinical research — closer to strategic medical infrastructure than to conventional charitable giving.

What is dievini Hopp BioTech? Hopp's biotech investment vehicle, formalised around 2005, managed by Friedrich von Bohlen und Halbach. Total deployment exceeds €1.4 billion across portfolio companies including CureVac, Heidelberg Pharma, AC Immune, Cosmo Pharmaceuticals, and others. Its patient-capital model is structurally different from venture capital and was decisive in anchoring CureVac through fifteen years of pre-commercial work.

What happened with CureVac? Hopp was CureVac's largest shareholder from 2005. In March 2020 he publicly rejected a reported Trump administration attempt to acquire US-exclusive vaccine rights, an episode that triggered KfW's €300 million investment in June 2020 and crystallised German vaccine sovereignty as a political priority. CureVac's first-generation COVID vaccine candidate failed in Phase 3 trials in June 2021 with only 47 percent efficacy. BioNTech completed the acquisition of CureVac for $1.25 billion in December 2025.

What is the 50+1 controversy around TSG Hoffenheim? German football's 50+1 rule requires club members to retain majority voting rights. Hopp was granted an exemption in 2015 due to his more than 20 years of significant investment. After years of conflict with fan groups, he announced in March 2023 he would return his majority voting rights to the club; the transfer was completed on November 29, 2023, restoring 50+1 compliance.

About the Author

Joern "Joe" Menninger is the founder of Startuprad.io, Europe's leading English-language startup media platform covering the DACH region. With 740+ podcast episodes and over 1 million annual streams. Connect on LinkedIn

Sources

• Dietmar Hopp Stiftung — Official

• KiTZ Heidelberg — Hopp Children's Tumor Center

• DKFZ — German Cancer Research Center

• SAP News Center — "SAP Co-Founder Dietmar Hopp Turns 80!" (April 2020)

• BioNTech — Completion of CureVac acquisition (December 2025)

• Der Spiegel — "Dietmar Hopp's New Hat: SAP Founder Builds German Biotech Empire" (June 2007)

• Fortune — "Billionaire German twins remake health and medicine" (Aug 2023)

• Handelsblatt — coverage of TSG Hoffenheim 50+1 transfer (Nov 2023)

• Kicker — investigation of Wittmann / Hoffenheim relationship (April 2025)

More on Startuprad.io

Read more in the SAP Founders Cluster: Friday's tribute to Claus Wellenreuther (1935-2026), Saturday's piece on Hasso Plattner and SAP as Europe's invisible operating system, and tomorrow's closer on Hans-Werner Hector, SAP's shadow architect. For the parallel story of German biotech founder-anchor capital and the BioNTech anchor that closed the loop on Hopp's CureVac bet, see our Strüngmann cluster anchor and the Twin Billionaires hub. See also our Power Structures: Hidden Champions and Ecosystem Gatekeepers pillar.